Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance

Award Number: R43AI155196
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/08/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2023

Group Awards By:

View Award Description

A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance - ABSTRACT Induction of immune tolerance with solid organ and vascular composite allografts is the Holy Grail for transplantation medicine. Induction of immune tolerance to mismatched grafts would obviate the need for life- long immunosuppression which is associated with serious adverse outcomes, such as renal failure, cancers and infections. Currently the most promising means of tolerance induction is through establishing a mixed chimeric state by transplantation of donor hematopoietic stem cells; however, with the exception of tolerogenic organs such as kidneys, the mixed chimerism approach has not achieved durable immune tolerance in preclinical or clinical trials with most solid organs or vascular composite allotransplants (VCA). Encouragingly, though, we have succeeded in achieving reduced immunosuppression in clinical trials of VCA using this approach. Mesenchymal stem (stromal) cells (MSC) are a potentially useful adjuvant to stem cell transplants (SCT) for promoting mixed chimerism as well as promoting complementary peripheral immunomodulatory functions. However, there are many unresolved issues to address before clinical translation of these promising therapeutic cells. A primary impediment is the source of MSC, which are rare in all tissues and require invasive procedures for procurement. Low abundance mandates extensive expansion in culture to generate sufficient numbers for human dosing. It has been observed in the clinical setting that the degree of expansion is negatively correlated with outcomes. Ossium Health has overcome this obstacle by identifying an abundant source of primary MSC associated with medullary bones of vertebral bodies obtained from deceased organ donors. These vertebral bone adherent MSC (vBA-MSC) are isolated by proteolytic digestion of bone fragments, following elution and cryopreservation of bone marrow (BM). Primary vBA-MSC are obtained at numbers that are 3 orders of magnitude higher than can be recovered from living donor iliac crest BM aspirates. A further advantage of vBA-MSC is they are matched to the donor, as opposed to third-party MSC, which enhances safety and potentially efficacy. Isolation and characterization of vBA-MSC from over 30 donors has demonstrated that the cells are no different than BM-MSC, but, because of their high numbers, unlike traditional BM-MSC, can be expanded to >5 billion cells with only 2 passages in culture. We hypothesize that donor-matched vBA-MSC will augment tolerance mechanisms of mixed chimerism with BM transplant as well as provide peripheral immunomodulatory functions to achieve durable tolerance for major histocompatibility complex mismatched solid organ and vascular composite tissue transplants. This hypothesis will be tested first in a murine orthotopic hind limb transplant VCA model and then in a murine heterotopic heart model. The hindlimb model studies will allow us to evaluate mechanisms of MSC immune tolerance due to the tolerogenic nature of BM-containing hind limbs. Durable grafts will be evaluated for T cell dynamics (especially memory T cells and regulatory T cells) and donor-specific immune tolerance with be confirmed with donor and third-party skin grafting. Information gained from this study will be used to perform similar studies in our heterotopic heart transplant model. If successful, the results of this study, combined with a plethora of MSC clinical trials as well as a long history of transplantation tolerance trials and our future Phase II studies to further define dosing parameters in small and large animal models, will provide compelling arguments to FDA for proceeding to clinical trials. Keywords: vascular composite allotransplantation; solid organ transplantation; immune tolerance; immunomodulation, regulatory T lymphocytes


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	OSSIUM HEALTH, INC.	78 TEHAMA ST	SAN FRANCISCO	CA	94105	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	2	3/27/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $142,485 )
2021	2021	OSSIUM HEALTH, INC.	1121 HOWARD ST	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	2	6/28/2021	NON-COMPETING CONTINUATION	$142,485
														Subtotal = $142,485

Issue Date FY: 2020 ( Subtotal = $157,465 )
2020	2020	OSSIUM HEALTH, INC.	25 TAYLOR ST	SAN FRANCISCO	CA	94102	SAN FRANCISCO	USA	Allergy and Infectious Diseases Research	000	1	7/8/2020	NEW	$157,465
														Subtotal = $157,465

Grand Total All Awards = $299,950

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance

Award Number: R43AI155196

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/08/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer